NICE approval of brigatinib in ALK-positive NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the approval of brigatinib for use in the first-line for patients with ALK-positive non-small cell lung cancer (NSCLC) by the National Institute for Health and Care Excellence (NICE) in the UK. Prof. Popat outlines how the UK's National Health Service (NHS) has adapted to this approval by allowing patients treated with first-line brigatinib to receive second-line lorlatinib. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.